|
|
Indinavir (Crixivan) Research
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
- High Dose of Vitamin C Significantly Reduces Indinavir Levels in Pilot Study (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- "Mono"-Therapy for HIV Infection Using Ritonavir-Boosted Indinavir (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Indinavir or Boosted Indinavir? (March 2002)
In Project Inform Perspective, from Project Inform
- Ingrown Toenails Still a Possible Side Effect (November 2001)
Indinavir-ritonavir interaction is possible culprit.
In HIV Treatment ALERTS!, from The Center for AIDS
- A Phase IV Randomized Open-Label Multicenter Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg BID) vs. Saquinavir/Ritonavir (1,000/100 mg BID) in Adult HIV-1 Infection: The Max Cmin 1 Trial (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Differential In Vitro Effects of Indinavir, Nelfinavir and Amprenavir On Cell Differentiation, Insulin Sensitivity and Apoptosis in an Adapted Adipose Cell Model -- Preventive Impact of Rosiglitazone (October 25, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) and Indinavir (IDV) In Treatment-Naive Patients Improves Therapeutic Outcome After 1 Year: Results from ATHENA (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- High Blood Pressure With Indinavir (May 25, 2001)
From Canadian AIDS Treatment Information Exchange
- Protease Combinations: Ritonavir and Indinavir One Year Later (March 15, 2001)
Developments from the 8th Conference on Retroviruses and Opportunistic Infections.
From Canadian AIDS Treatment Information Exchange
- ACTG 5056: Metabolic Status and Cardiovascular Disease Risk for a Cohort of HIV-1-Infected Persons Durably Suppressed on an Indinavir-Containing Regimen (ACTG 372A) (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Indinavir/Ritonavir Versus Indinavir in Combination With AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: A Randomized, Open-Label Trial (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Preliminary Results From Indinavir (IDV) and Ritonavir (RTV) in a Once-Daily Regimen (Marck 103/104) (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Is Once Daily Indinavir With Ritonavir On the Way? (December 20, 2000)
From Canadian AIDS Treatment Information Exchange
- Saliva Useful for Monitoring Indinavir Levels in HIV-Infected Patients (October 2000)
In Body Positive, from Body Positive
- Abacavir vs. Indinavir in Therapy-Naive People (CNA3014) (August 17, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Ritonavir Intensification of Indinavir in People Without Complete HIV Suppression (August 17, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- A Randomized, Controlled, Open-label Study Comparing the Adherence and Convenience of Continuing Indinavir Q8H vs. Switching to Norvir/Indinavir 400 mg/400 mg BID (The NICE Study) (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Long-Term Comparative Outcomes of Indinavir (IDV) vs. Nelfinavir (NFV)-Based HAART in Naive Patients in Routine Clinical Practice (July 12, 2000)
The Body's Coverage of the XIII International AIDS Conference.
In The XIII International AIDS Conference, from The Body PRO
- Once-a-Day Indinavir Therapy in Virologically Controlled HIV-Positive Persons (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Viral Rebound in the Presence of Indinavir Without Protease Inhibitor Resistance (February 4, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Co-Administration of Indinavir 1200 mg with Nelfinavir 1250 mg in a Twice Daily Regimen: Preliminary Safety, PK Activity (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Co-Administration of Indinavir 1,200 mg (IDV) and Nelfinavir (NFV) 1,250 mg in a Twice Daily Regimen: Preliminary Safety, Pharmacokinetic (PK) and Anti-Viral Activity (November 14, 1998)
In The 36th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Indinavir 12 Hour Dosing an Alternative to 8 Hourly Dosing Regimen: A Pilot Study (July 3, 1998)
In The 12th International AIDS Conference, from The Body PRO
- Two-Year Durability of HIV-1 Viral Load Suppression in Patients Treated With Indinavir Who Experience Virus Load Declines to <500 VRNA Copies/mL (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
- Efavirenz + Indinavir (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm3 (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Indinavir Pharmacokinetics and Menstrual Cycle Physiology (February 3, 1998)
From Seattle Treatment Education Project
- The START Trials (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Thirty-Two Week Follow-Up of Indinavir Sulfate Administered Q8 Hours Versus Q12 in Combination With Zidovudine and Lamivudine (February 3, 1998)
From Seattle Treatment Education Project
- Triple Combination Therapy Including Indinavir Is Effective in Advanced AIDS (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Two Year Follow-Up of Patients Treated With Indinavir (Crixivan) (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
|
